1Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: Signaling through lipid rufts[J]. Immunology. 2002,107(2) : 176-182. 被引量：1
2Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells [J]. Cancer Immunol Immunother, 2000,48 (12) : 673-683. 被引量：1
3McLaughlin P, Antonio J, Grillo2Lopez AJ , et al Riruximab chimeric Anti CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients responded for a four2dose treatment program[J]. J Clin Oncol, 1998,16(8) :2825-2833. 被引量：1
4Davis TA, Grillo- Lopez AJ, White CA, el al. Rituximab anti CD20 monoclonal antibody therapy in non Hodgkin's lymphoma: safety and efficacy of re-treatment[J]. J Clin Oncol, 2000 18(17): 3135-3143. 被引量：1
5Hochster HS, Weller E, Ryan T, et al. Results of E1496: a phase Ⅲ trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)[J]. Proc Am Soe Clin Oncol, 2004, 22(14S): 6502. 被引量：1
6Pfreundschuh MG, Trumper L, Ma D, et al. Randomized in tergroup trial of first line treatment for patients ≤ 60 years with diffuse large B- cell non-Hodgkin's lymphoma(DI.BCL) with a CHOP like regimen with or without the anti CD20 an tibody rituximab early stopping after the first interimanalysis [J]. Proc Am Soc Clin Oncol, 2004, 22(14s): 6500. 被引量：1
7Thomas C , Foulet A , Plat M,et al. Efficacy of rituximab in lymphoma2 toid granulomatosis[J]. Rev Mal Respir, 2004, 21 (6) :1157. 被引量：1
4[1]Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatmentof patients with chronic idiopathic thrombocytomenic purpura refractory to cortiscosteroid or splenectomy[J]. Br J Haematol, 2001,114:121～125. 被引量：1
5[2]Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatmeut for adults with chronic idiopathic thrombocytopenic purpura[J]. Blood,2001,98:952～957. 被引量：1
6[3]Tedder TF, Engel P. CD20 a regulator cell cycle progression of B-lymphocyte[J]. Imunol Today, 1994,15:450. 被引量：1
7[5]Emilia G, Messora C, Longo G, et al. Long-term salvage treatment by cyclospor in refractory autoinnune haematological disorders[J]. Br J Haematol,1996,93:34～344. 被引量：1
8[6]Maloney DG, Smith B, Applebaum FR. The anfitumor effect of monoclonal anti CD20 antibody therapy includes anti-proliferation activity and induction of apoptosis in CD20 positive NHL cell lines[J]. Blood, 1996, 88:637a. 被引量：1
9[7]Maloney KG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma[J]. Blood,1994,84:2457～2466. 被引量：1
10[8]McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric antiCD20 monoclonal antibody theraphy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program[J]. J Clin Oncol, 1998,16: 2825～2833. 被引量：1
5Mayers CP.Histological fixation by microwave heating[J].Clin Pathol,1970,23 (3):273-275. 被引量：1
6Leong AS-Y.Microwaves and turnaround times in histopathology:is this a new era in histotechnology?[J].Am J Clin Pathol,2004,121 (4):460-462. 被引量：1
7Morales AR,Essenfeld H,Essenfeld E,et al.Continuous-specimen-flow,high-throughput,1-hour tissue processing:a system for rapid diagnostic tissue preparation[J].Arch Pathol Lab Med,2002,126(5):583-590. 被引量：1
8Rohr LR,Layfield LJ,Wallin D,et al.A Comparison of routine and rapid microwave tissue processing in a surgical pathology laboratory:quality of histologic sections and advantages of microwave processing[J].AmJClinPathol,2001,115(5):703-708. 被引量：1
9Leong AS-Y,Milios M.Accelerated immunohistochemical staining by microwaves[J].J Pathol,1990,161(4):327-334. 被引量：1
10Lyska L,Emerson,Sheryl R,et al.A Comparison of Immunohistochemical Stain quality in conventional and rapid microwave precessed tissues[J].Am J Clin Patho1,2006,125 (2):176-183. 被引量：1
